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Abstract
Background: Biochemical bone turnover markers (BTM) 
are useful tools to assess bone remodeling at the cellular 
level. N-terminal propeptide of type I procollagen (PINP) 
has been recommended as a reference marker for bone 
formation in research studies.
Methods: We describe the results of a multicenter study 
for routine clinical laboratory assays for PINP in serum 
and plasma. Four centers (Athens, Greece [GR], Copen-
hagen, Denmark [DK], Liege, Belgium [BE] and Shef-
field, United Kingdom [UK]) collected serum and plasma 
(EDTA) samples from 796 patients presenting to osteopo-
rosis clinics. Specimens were analyzed in duplicate with 
each of the available routine clinical laboratory methods 
according to the manufacturers’ instructions. Passing-
Bablok regressions, Bland-Altman plots, V-shape evalua-
tion method and the concordance correlation coefficient 
for PINP values between serum and plasma specimens 
and between methods were used to determine the agree-
ment between results. A generalized linear model was 
employed to identify possible variables that affected the 
relationship between the methods.
Results: We showed that both EDTA plasma and serum 
were suitable for PINP determination. We observed a 
significant proportional bias between Orion radioim-
munoassay and the automated methods for PINP (Roche 
Cobas and IDS iSYS), which both gave very similar results. 
The multivariate model did not improve the excellent cor-
relation that was observed between the methods.
Conclusions: Harmonization of PINP assays is possible by 
applying a correction factor or correctly assigning the val-
ues of the calibrators. This work will benefit from further 
collaboration between assays manufacturers and clinical 
laboratory professionals.
Keywords: bone marker; bone turnover; bone turnover 
markers; harmonization; N-terminal propeptide of type I 
procollagene; propeptide of type I procollagen (PINP).
Introduction
Osteoporosis is a major disease characterized by low bone 
mass and microarchitectural deterioration of bone tissue, 
leading to an increased risk of fracture, morbidity and 
mortality. Its prevalence is increasing with aging of the 
population and the global burden of this disease and its 
complications in the European Union has been estimated 
at €37 billion per year [1]. Clinical and pharmacological 
management of osteoporosis consists in the prevention or 
reduction of fracture risk and monitoring the response to 
therapy. For that purpose, measurement of bone turnover 
biochemical markers could be of great interest. A consen-
sus paper published in 2010 by the International Osteopo-
rosis Foundation (IOF) and the International Federation of 
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Clinical Chemistry and Laboratory Medicine (IFCC) Joint 
Working Group on Bone Marker Assays (WG-BMA) recom-
mended one bone formation marker, namely the procol-
lagen type I N-propeptide (PINP) and one bone resorption 
marker, the C-terminal telopeptide of type I collagen 
(CTX) be used as reference markers for clinical research 
studies [2]. A few years later, the IOF and European Calci-
fied Tissue Society (ECTS) proposed that PINP and CTX be 
measured at baseline and after 3 and 12 months of treat-
ment with oral bisphosphonates to assess adherence to 
therapy [3].
PINP is a trimer constituted by three non-covalently 
linked type I collagen subunit chains (two pro-α1 and one 
pro-α2 chains) presenting a molecular mass of 35 kDa [4]. 
Type I collagen is synthesized by osteoblasts and depos-
ited in the resorption cavity during bone formation phase. 
The aminoterminal propeptide is cleaved enzymatically 
during the last phase of maturation and is then released 
in the circulation where it is rapidly bound and internal-
ized by the endothelial cells of the liver. In human serum, 
PINP is present in two major forms, a trimeric and a mono-
meric form, this latter being elevated in patients suffer-
ing from chronic renal failure. The serum concentration of 
PINP shows little diurnal or seasonal variation and is little 
influenced by food intake, which is an important advan-
tage over CTX (an extensive review on factors influencing 
bone turnover markers can be found in [5]).
Currently there are two commercially available auto-
mated immunoassays for the detection of PINP in serum 
and/or plasma, from Immunodiagnostic Systems plc 
on the iSYS automated analyzer (IDS, Boldon, UK) and 
from Roche Diagnostics (Mannheim, Germany) on the 
cobas e family instruments and one manual radioim-
munoassay (RIA) from Orion Diagnostica (UniQ PINP 
RIA, Orion Diagnostica, Espoo, Finland). However, these 
kits are not equivalent, as they do not recognize to the 
same extent the monomeric form of the peptide: the 
“Total” PINP assay (Roche Elecsys) recognizes both the 
trimeric and the monomeric forms whereas the “Intact” 
PINP assays (IDS iSYS and Orion Diagnostica) recognize 
the trimeric form only. As the monomers accumulate in 
patients suffering from chronic kidney diseases (particu-
larly when the glomerular filtration rate is lower than 
30  mL/min/1.73  m2), they will interfere with the “total” 
PINP assay from Roche, leading to spuriously elevated 
PINP results [6]. This is also the case with bedridden ger-
iatric patients [7] and with patients suffering from breast 
cancer [8].
Previous studies have shown that there is some dis-
agreement between the results generated from patient 
samples by the three PINP assays [8–13].
Hence, in order to establish the clinical value of PINP 
as a reference bone biomarker, harmonization of the 
results from different assays for this biomarker is neces-
sary in people with normal renal function. In this paper, 
we now report the results of a study conducted by the 
Joint Committee IFCC-IOF for Bone Metabolism (C-BM) to 
compare the PINP results generated by each of the avail-
able routine clinical assays of patients presenting to oste-
oporosis clinics.
Materials and methods
Patients and samples
Four centers located in Athens (Greece, GR), Copenhagen (Denmark, 
DK), Liege (Belgium, BE) and Sheffield (United Kingdom, UK), experi-
enced with performance of these assays, took part in the study. After 
a familiarization experiment, and according to the agreed protocol, 
each center recruited 200 patients attending a local osteoporosis 
clinic. Approval by a local Research Ethics Committee was obtained 
for each center with all participating patients signing an informed 
consent form.
Patient blood samples were collected in K3-EDTA tubes for 
analyses on plasma and in tubes with gel for analyses on serum. 
Separation of plasma and serum was achieved in the hour following 
the sampling and aliquots were stored at −80 °C until PINP deter-
mination (maximum 2 years). Demographic data, including sex, age 
fasting status, current medications and areal bone mineral density 
(BMD) were also collected. BMD was measured at the lumbar spine 
(L1–L4) and at the total hip by dual-energy X-ray absorptiometry 
(DXA) with a Hologic instrument in three centers and with a Lunar 
machine in one center. The transformation of BMD into standardized 
BMD (sBMD) was performed according to the equations published by 
Genant et al. [14].
During the familiarization experiment, each center was asked to 
run two serum pools in five replicates over 5 consecutive days, with 
each method, without recalibration according to CLSI EP15-A3 [15]. 
This performance study was run in parallel with the measurements 
of the patients’ samples. The two serum pools were constituted in 
BE using remnant human samples that had been stored at −80 °C 
for >5 years. These samples were mixed together according to their 
original value to target a final PINP concentration of ≈30 and ≈150 
μg/L. After thorough homogenization during 1 h on a rotating plate, 
pools were centrifuged and aliquoted. The aliquots were stored at 
−80 °C until shipment on dry ice to each participating center. Each 
center thus received five aliquots (one for each day) for each instru-
ment. Up to three to five cycles of freeze-thaw do not have a signifi-
cant effect on measured PINP [12]. Evaluation of the imprecision was 
performed according to the biological variability concept and the 
goals were classically calculated as z × (coefficient of variation (CV)
w where z = 0.50 and 0.75 for desirable and minimal imprecision and 
CVw is the within-individual coefficient of variation. We reviewed the 
literature available on PINP biological variability (Table 1) and found 
that the median CVw for PINP was 7.3%. Hence, the desirable and 
minimal CV should be 3.7% and 5.5%.
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Analytical methods
The IVD companies producing PINP assay kits (IDS, Roche and Orion 
Diagnostica) provided reagents and calibrators to the participating 
laboratories. All reagents were from the same lot and a single calibra-
tion was used (except for the RIA). For Roche, the cobas e411 analyzer 
was the instrument used in all centers. All the laboratories had previ-
ous experience in running these methods and all assays were run in 
all laboratories, except Orion Diagnostica RIA which was only run in 
BE and DK.
Roche and IDS claim that PINP can either be measured in serum 
and plasma whereas Orion Diagnostica only claims the use of serum. 
Plasma and serum samples were run in duplicate on all methods 
according to the manufacturers’ instructions (and with the agreement 
of Orion to also use EDTA plasma for their method) and results were 
calculated if the standard curves and the manufacturers’ supplied 
internal quality control (QC) specimens were within the specifications. 
All measurements took place between December 2016 and March 2017.
Statistical methods
MedCalc (Mariakerke, BE) was used to calculate the Passing-Bablok 
regressions between serum and plasma and between methods as 
well as Bland-Altman plots. The coefficients of variation were calcu-
lated on duplicates to determine the repeatability of each assay. The 
mean of the duplicates was used to compare the results. The Mann-
Whitney test was used to compare the medians.
The familiarization panel was analyzed per level using an ANOVA 
model accounting for the effects of center, day and the interaction 
between day and center and the QC results between centers were com-
pared with ANOVA, followed by Tukey’s multiple comparison test with 
the 95% confidence intervals (CIs) method (Graphpad Prism 6).
If the agreement between results would indicate considerable 
deviation from the ideal situation (slope ≠ ‘1’, intercept ≠ ‘0’, R2 ≠ 1), 
we had decided to use the GLMSELECT procedure, using the back-
ward selection option in SAS 9.4, to establish a generalized linear 
model (GLM) for each comparison with the aim to identify variables 
which affected the differences between methods and ultimately to 
obtain a more acceptable prediction model. GLMSELECT provides 
t-values for the coefficients (instead of p-values). An absolute t-value 
>1.96 corresponds with a p-value <0.05. The larger the absolute 
t-value, the more important the coefficient in the GLM.
As small deviations from the ideal situation will be statistically 
significant because of the (very) large sample size of this study, we 
reviewed the literature on PINP biological variation (Table 1) which 
allowed us to define specifications corresponding to a desirable bias 
of ±9.3% for the slope and ±5 μg/L for the intercept corresponding to 
the limit of quantification of the assays to build V-shape limits (defined 
as y = − 0.093 x – 5 and y = 0.093 x + 5) for the regression of differences 
on averages. We calculated the percentages of samples comprised 
between the V-shape limits and considered that methods were equiva-
lent if 90% of the samples were comprised within the limits.
Finally, we calculated the concordance correlation coefficients 
(CCC) factor, which evaluates the degree to which pairs of observa-
tions fall on the 45° line through the origin according to Lin et al. [20] 
and the strength of agreement according to McBride et al. [21] as well 
as the Pearson correlation coefficient (ρ), which measures how far 
each observation deviates from the best-fit line, and is thus a meas-
ure of precision, and a bias correction factor (Cb) that measures how 
far the best-fit line deviates from the 45° line through the origin, and 
is thus a measure of accuracy.
Results
All the calibration curves were accepted by the instru-
ments and all the QCs were within the specifications pro-
vided by the manufacturers.
Table 1: Biological variation of PINP.
First author and reference  Population   Assay   Scheme   CVw   CVg   Desirable 
CV, %
  Desirable 
bias, %
Healthy subjects
 Alvarez, 2000 [16]   12 healthy 
premenopausal women
  Orion RIA  From two to five samples 
(median: 4) per person 
over a period of 1 year
  6.2%   18.4%   3.1%  4.9%
 Hannon 1998 [17]   11 postmenopausal 
women
  Orion RIA  Four samples: at months 0, 
1, 13 and 25
  7.4   NA   3.7%  NA
 Garnero, 2008 [13]   15 untreated 
postmenopausal women
  Roche 
Elecsys
  Three samples: baseline, 
day 30 and day 90
  7.2%
p25–p75
5.3–13.9
  NA   3.6%  NA
 Clowes 2002 [18]   10 fasting premenopausal 
women
  Roche 
Elecsys
  Five samples, 1 every 
2 days, 10 days
  10.6%   NA   5.4%  NA
 Rogers 2009 [19]   51 postmenopausal 
women
  Orion RIA  Two samples, at two  
time-points, 2 weeks apart
  9.1%   NA   4.6%  NA
 Cavalier (not published)  22 healthy individuals 
(11 males and 11 females)
  IDS iSYS   Five samples, one sample 
per week
  5.9%   30.8%   3.0%  7.8%
MEDIAN   7.3%   24.6%   3.7%  6.4%
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Patients
Seven hundred and ninety-six patients (692  women, 
104 men) were included in the study. The mean age (±SD) 
was 66.1 (±11.7) years and mean BMI was 25.9 (±4.8) kg/m2. 
There were mean age differences for patients recruited at the 
various centers: GR had the youngest patient group (mean 
age = 61.6 ± 8.8) and DK had the oldest patient group (mean 
age = 70.1 ± 11.3). All patients were in a fasting status in BE 
and GR whereas this was not necessarily the case in DK and 
UK. Regarding their treatment, 65.8% were taking calcium, 
60.8% vitamin D, 11.1% active vitamin D, 25.9% bisphospho-
nates, 0.3% strontium ranelate, 9.0% denosumab, 2.0% teri-
paratide and 1.1% was treated by selective estrogen receptor 
modulators. The median sBMD was 814 mg/cm2 (interquar-
tile range [IQR]: 798–827 mg/cm2) at the spine and 753 mg/
cm2 (IQR: 743–764 mg/cm2) at the hip. None of the patients 
presented an eGFR lower than 30 mL/min/1.73 m2.
Imprecision of the methods and performance 
evaluation study
The mean of pools were different according to the methods: 
30.5 ± 1.6 μg/L and 156.0 ± 8.0 μg/L for Elecsys on level 1 and 
2, respectively, vs. 30.8 ± 2.4 μg/L and 174.0 ± 12.0 μg/L for 
iSYS and 25.7 ± 2.2 and 132.0 ± 24.0 μg/L for Orion RIA. The 
imprecision of the methods according to the CLSI EP15-A3 
guideline, is presented in Table 2. As expected, the manual 
RIA method presented higher CVs than the automated ones, 
and this was especially true for pool 2. The ANOVA results 
showed that for iSYS, the center was the major source of 
variability whereas for the two other methods, both center 
and day significantly influenced the results.
For iSYS, the CV ranged between desirable (3.7%) 
and minimal (5.5%) CV for all centers, except in GR 
which presented CVs higher than the minimal CV. There 
are no clear explanations why GR presented higher 
CVs than the other three centers: all the QC were in the 
manufacturer’s range and the operating conditions were 
totally controlled. A lack of homogenization of the frozen 
samples might be the explanation. For Elecsys, the CV 
ranged between the desirable and minimal (6.2%) CV for 
all centers and for the RIA, all CVs were higher than the 
minimal CV (Table 2).
Comparison plasma vs. serum
All Passing-Bablok regressions for method comparisons 
of the same assay in serum and plasma are presented in 
Table 3. All the slopes were comprised between 0.94 and 
1.05. The V-shape model (Figure 1) shows that more than 
95% of the observations fitted within the limits with very 
little center disparities showing that the test gave equiva-
lent results on both serum and plasma.
Comparison of methods in plasma and serum
Roche Elecsys vs. IDS iSYS
In plasma, the Passing-Bablok regression on the relationship 
between Elecsys and iSYS was: Roche Elecsys = 0.86 × IDS 
iSYS + 2.9 and in serum, it was: Roche Elecsys = 0.91 × IDS 
iSYS + 2.6 (Table 4). The Bland-Altman plots and the 
V-shaped models (Figure 2A and B) show that, overall, 
87.4% and 86.1% of the values were within the limits for 
serum and plasma, respectively (chi-square [χ2] = NS). There 
was some disparity between the centers, with a percentage 
of agreement ranging from 81.8% in BE to 93.2% in DK for 
serum and from 78.0 in the UK to 92.2% in GR for plasma.
Roche Elecsys vs. Orion RIA
In plasma, the Passing-Bablok regression on the relation-
ship between Elecsys and Orion RIA was: Elecsys = 1.24 ×  
Orion RIA-0.2 and in serum, it was: Elecsys = 1.22 × Orion 
Table 2: Imprecision (CV%) of Roche Elecsys, IDS iSYS and Orion Diagnostica RIA of PINP assays according to the CLSI EP15-A3 guideline.
Roche Elecsys IDS iSYS Orion RIA
Pool 1 Pool 2 Pool 1 Pool 2 Pool 1 Pool 2
Mean ± SD, μg/L 30.5 ± 1.6 156.0 ± 8.0 30.8 ± 2.4 174.0 ± 12.0 25.7 ± 2.2 132.0 ± 24.0
ALL 5.1 5.2 7.7 6.7 8.6 18.1
BE 3.1 3.4 3.2 3.0 7.1 20.5
DK 4.5 4.6 3.9 3.7 9.9 11.3
GR 4.5 3.1 8.4 7.6 NP NP
UK 5.0 5.2 3.2 2.3 NP NP
The values in italics are those higher than the desirable CV (3.7%) and those in bold higher than the minimal CV (5.5%), based on  
intra-individual variation of the biomarker. NP, not performed.
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Table 3: Passing-Bablok correlation between PINP run in plasma (y) and serum (x).
Roche Elecsys IDS iSYS Orion Diagnostica
ALL
 Slope (95% CI) 0.98 (0.97; 0.98) 1.03 (1.02; 1.04) 0.98 (0.96; 1.00)
 Intercept (95% CI) −0.1 (−0.4; 0.1) −0.4 (−0.7; −0.1) −0.1 (−0.5; 0.3)
 n 796 794 383
BE
 Slope (95% CI) 1.01 (0.99; 1.03) 1.05 (1.04; 1.07) 1.00 (0.98; 1.03)
 Intercept (95% CI) −0.3 (−0.9; 0.4) 2.7 (2.0; 3.5) −0.4 (−1.3; 0.3)
 n 200 198 200
DK
 Slope (95% CI) 0.95 (0.94; 0.97) 1.01 (0.99; 1.02) 0.94 (0.92; 0.96)
 Intercept (95% CI) −0.0 (−0.3; 0.4) −0.30 (−0.56; −0.01) 0.4 (−0.1; 0.9)
 n 192 192 183
GR
 Slope (95% CI) 0.97 (0.96; 0.99) 0.99 (0.97; 1.01) NP
 Intercept (95% CI) −0.1 (−0.9; 0.6) −0.1 (−1.2; 0.8)
 n 204 204
UK
 Slope (95% CI) 0.96 (0.95; 0.97) 1.05 (1.03; 1.06) NP
 Intercept (95% CI) 0.2 (−0.3; 0.7) −0.2 (−0.9; 0.5)
 n 200 200
NP, not performed.
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Figure 1: Bland-Altman plots and V-shape models comparing values observed in serum vs. plasma with Roche Elecsys (A), IDS iSYS (B) and 
Orion RIA (C).
More than 95% of the observations fit within the limits showing that the results are equivalent in serum and plasma.
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Table 4: Passing-Bablok regression analyses of PINP values performed with Roche Elecsys, IDS iSYS and Orion RIA assays on serum and 
plasma specimens.
Plasma
 
 
X
IDS iSYS  
 
Orion RIA
Y All All
Roche Elecsys
 Slope (95% CI)   0.86 (0.85; 0.87)   1.24 (1.21; 1.27)
 Intercept (95% CI)  2.9 (2.5; 3.2)   −0.2 (−1.1; 0.6)
 n   794   382
IDS iSYS
 Slope (95% CI)     1.45 (1.42; 1.48)
 Intercept (95% CI)    −3.7 (−4.5; −2.9)
 n     381
X
 
 
iSYS  
 
Orion RIA
Y BE   UK   GR   DK BE   UK   GR   DK
Roche Elecsys
 Slope (95% CI)   0.85 (0.83; 0.87)   0.86 (0.84; 0.89)   0.87 (0.85; 0.90)   0.89 (0.86; 0.92)   1.26 (1.21; 1.30)   NP   NP   1.34 (1.28; 1.41)
 Intercept (95% CI)  2.4 (1.7; 3.0)   1.5 (0.5; 2.2)   4.1 (3.0; 5.2)   2.8 (2.3; 3.2)   −2.0 (−3.0; −0.8)       −0.8 (−1.8; 0.7)
 n   198   200   204   192   199       183
IDS iSYS
 Slope (95% CI)     1.45 (1.41; 1.49)   NP   NP   1.48 (1.44; 1.53)
 Intercept (95% CI)    −4.7 (−6.1; −3.5)       −4.0 (−4.9; −2.9)
 n     199       183
Serum
 
 
X
IDS iSYS  
 
Orion RIA
Y All All
Roche Elecsys
 Slope (95% CI)   0.91 (0.90; 092)   1.22 (1.19; 1.26)
 Intercept (95% CI)  2.6 (2.2; 3.1)   0.0 (−0.7; 1.2)
 n   794   387
IDS iSYS
 Slope (95% CI)     1.35 (1.32; 1.38)
 Intercept (95% CI)    −3.2 (−3.8; −2.4)
 n     386
 
 
X
IDS iSYS  
 
Orion RIA
Y BE   UK   GR   DK BE   UK   GR   DK
Roche Elecsys
 Slope (95% CI)   0.89 (0.87; 0.92)   0.95 (0.92; 0.98)   0.89 (0.86; 0.92)   0.95 (0.93; 0.98)   1.24 (1.19; 1.29)   NP   NP   1.31 (1.26; 1.35)
 Intercept (95% CI)  2.5 (1.5; 3.5)   0.8 (−0.5; 2.1)   3.7 (2.1; 5.1)   2.5 (1.9; 3.0)   −1.9 (−3.5; −0.2)       0.6 (−0.3; 1.5)
 n   198   200   204   192   199       188
IDS iSYS
 Slope (95% CI)     1.38 (1.35; 1.42)   NP   NP   1.36 (1.31; 1.40)
 Intercept (95% CI)    −4.6 (−5.8; −3.5)       −1.9 (−3.2; −1.1)
 n     198       188
The upper line of result corresponds to the slope (95% CI) and the second line to the intercept (95% CI). NP, not performed.
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RIA-0.0 (Table 3). The Bland-Altman plots (Figure 2C and D) 
shows an important proportional bias and the V-shape 
limits show an overall agreement of 61.1% for serum 
vs. 60.3% for plasma (χ2 = NS). The percentage of agree-
ment was significantly higher in BE than in DK.
IDS iSYS vs. Orion RIA
In plasma, the Passing-Bablok regressions on the rela-
tionship between IDS iSYS and Orion RIA was IDS 
iSYS = 1.45 × Orion RIA-3.7 and in serum, the relation was 
IDS iSYS = 1.35 × Orion RIA-3.2 (Table 3). The Bland-Altman 
plots also show an important proportional bias (Figure 
2E and F) and the V-shape limits showing percentages of 
samples between the limits of 57.4% in serum vs. 49.1% in 
plasma (χ2 = 0.09).
To identify factors contributing to the variation between 
the PINP values generated by the three assays, we calculated 
multivariable models with age, sex, center, BMI, weight, 
height, BMD, fasting status and medication as independent 
covariates (data not shown). Due to the excellent correla-
tion between the measurements (univariate R2 ≥ 0.97), the 
multivariate models only marginally improved the results. 
The concordance correlation coefficient, which takes preci-
sion and accuracy into consideration is substantial (>0.95) 
when we compared the two automated methods, whereas it 
was poor (<0.90) when they were compared with the Orion 
RIA (Table 5), either for serum or plasma. The explanation 
for the poor performance when Orion RIA was taken into 
consideration was not due to the precision (ρ), which was 
>0.97, but rather to a poor accuracy between the manual 
and automated methods whereas it was of 0.99 when both 
automated methods were compared together.
Figure 2: Bland-Altman and V-shape models comparing values observed in serum vs. plasma on iSYS vs. Elecsys (A and B), Elecsys vs. Orion 
RIA (C and D) and iSYS vs. Orion RIA (E and F).
The Bland-Altman plots show a significant proportional difference between Orion RIA and both automated methods from Roche and IDS, 
which show a rather good agreement.
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Discussion
Bone turnover markers are commonly used to monitor 
osteoporotic patients’ response to pharmacological treat-
ment and monitoring compliance [3]. They have the great 
advantage, over bone mineral densitometry, to change 
rapidly according to treatment and these changes have 
been shown to correlate with reduction in fracture risk 
[22].  Hence, the IOF and IFCC have established a Working 
Group for the standardization of bone marker assays, 
whose task was to standardize or harmonize (as techni-
cally feasible or appropriate at this time) bone markers 
assays available for routine and research use, in serum 
and EDTA plasma. The WG has decided to compare the 
results of BTM in a very well-defined multicenter cohort of 
approximately 800 patients attending osteoporosis clinics. 
This comparison was achieved in serum and plasma, 
with the different commercially available methods that 
are routinely used. In this study, we report the results of 
PINP evaluation. PINP is a bone formation marker which 
presents very interesting features, namely a very limited 
impact of food consumption [18] and circadian variation 
[23] on the results. PINP has thus been recommended by 
the IOF-IFCC WG as the reference bone formation marker. 
PINP is present in two major forms, the trimeric form and 
a monomeric one, this latter being elevated in patients 
suffering from chronic renal failure.
Different reports have already evaluated PINP as 
measured by IDS iSYS, Roche Elecsys and Orion RIA. In 
72 self-reported healthy volunteers and 55 patients suffer-
ing from rheumatoid arthritis (RA), Wheater et al. found 
a median difference of 2.0 μg/L between Elecsys total 
PINP and iSYS intact PINP in serum, with Roche giving 
significantly higher PINP concentrations compared to 
IDS (p < 0.001) [9]. In our study, the median difference 
observed between the two methods was 0.25 μg/L (not 
significant). The Passing-Bablok regression equation in 
Wheater’s et al. study was IDS = 0.98 × Roche – 1.4; with 
a slope not significantly different from 1.0, the intercept 
being significantly different from 0.0, whereas we found 
that the slope and intercept of the Passing-Bablok in our 
study were significantly different from 1 to 0, may be due 
to a higher number of observations and a higher range 
of measurement. The Bland-Altman plot showed a bias 
of 2.6 (Roche-IDS) with 95% limits of agreement ranging 
from −13.1 to 18.2 but the authors showed positive dif-
ferences between total and intact assays at higher (>80 
μg/L) levels, mainly found in patients suffering from RA. 
This gave a funnel shape of the Bland-Altman plot and the 
discrepancy was explained by the presence of monomers 
in RA patients. We did not have the information on RA in 
our patients, but the Bland-Altman plot showed a bias 
of 1.3 with 95% limits of agreement ranging from −15.1 to 
17.7. In 2008, Garnero et al. [13] found that, in 59 healthy 
pre- and postmenopausal women, serum Elecsys values 
were on average 9.8 μg/L higher than those obtained by 
Orion RIA and that was a trend in increased difference 
between the two methods with increasing PINP concen-
trations. This is in line with our results as we observed 
a median difference of 12.5 μg/L and an important pro-
portional bias. Like us, Koivula et  al. [10] observed an 
excellent correlation between IDS iSYS, Roche Elecsys 
and Orion RIA. Finally, one of us compared the Roche 
and IDS assays in a large population of 2308 individuals. 
The result showed a R2 of 0.8573 (much lower than our 
results) and a significant mean difference of 3 μg/L.
These findings combined to the results we present in 
this study clearly show a significant proportional difference 
Table 5: Concordance correlation coefficients (CCC), Pearson’s 
correlation coefficient (ρ), which measures the precision and bias 
correction factor (Cb) which measures the accuracy.
 
 
IDS iSYS  
 
Orion RIA
All All
Plasma
 Roche Elecsys
  CCC (95% CI)   0.9649  
(0.9604–0.9689)
  0.8905  
(0.8746–0.9044)
  ρ   0.9765   0.9713
  Cb   0.9881   0.9168
  Strength of agreement   Substantial   Poor
 IDS iSYS
  CCC (95% CI)     0.8386  
(0.8193–0.8560)
  ρ     0.9784
  Cb     0.8572
  Strength of agreement     Poor
Serum
 Roche Elecsys
  CCC (95% CI)   0.9706  
(0.9664–0.9743)
  0.8883  
(0.8719–0.9027)
  ρ   0.9722   0.9630
  Cb   0.9984   0.9224
  Strength of agreement   Substantial   Poor
 IDS iSYS
  CCC (95% CI)     0.8760  
(0.8605–0.8898)
  ρ     0.9812
  Cb     0.8927
  Strength of agreement     Poor
The CCC evaluates the degree to which pairs of observation fall on 
the 45° line through the origin and corresponds to ρ · Cb. NP, not 
performed.
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between Orion RIA and both automated methods. This bias 
can certainly be due to a difference in the assignment of 
the calibrator’s values. As there are excellent correlations 
observed between the methods, the good news is that a 
harmonization of the methods should be possible. This har-
monization will however be restricted to patients present-
ing GFR above 30 mL/min/1.73 m2 as below this threshold, 
monomers start to accumulate and interfere with the total 
PINP assay from Roche. The next steps should thus include 
the preparation of a commutable international reference 
material for common calibration of the different assays and 
the development of a reference method as needed.
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